Article

Breast cancer metastasis: Markers and Models

Division of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Nature reviews. Cancer (Impact Factor: 37.4). 09/2005; 5(8):591-602. DOI: 10.1038/nrc1670
Source: PubMed

ABSTRACT

Breast cancer starts as a local disease, but it can metastasize to the lymph nodes and distant organs. At primary diagnosis, prognostic markers are used to assess whether the transition to systemic disease is likely to have occurred. The prevailing model of metastasis reflects this view--it suggests that metastatic capacity is a late, acquired event in tumorigenesis. Others have proposed the idea that breast cancer is intrinsically a systemic disease. New molecular technologies, such as DNA microarrays, support the idea that metastatic capacity might be an inherent feature of breast tumours. These data have important implications for prognosis prediction and our understanding of metastasis.

Download full-text

Full-text

Available from: Laura J van 't Veer, Aug 11, 2015
  • Source
    • "Invasion and angiogenesis are key steps of the metastatic process of breast cancer [2] [11]. Vascular endothelial growth factor (VEGF) [12] [13] and platelet-derived growth factor-C (PDGF-C) [14] [15] are important mediators of angiogenesis. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Breast cancer is one of the most common malignant diseases in women. The main cause of death from breast cancer is its metastases at distant sites in the body. Interleukin-33 (IL-33) is a cytokine of the IL-1 family and found overexpressed in various cancers. The aim of the present study was to explore the association of serum IL-33 and sST2 with breast cancer. Here, the serum levels of Interleukin-33 (IL-33) and sST2 were found significantly higher in breast cancer patients than in healthy volunteers. Serum levels of vascular endothelial growth factor (VEGF), metalloproteinase-11 (MMP-11), and platelet-derived growth factor-C (PDGF-C) were also greater in breast cancer patients compared to healthy volunteers. We found that serum levels of IL-33 or sST2 were positively correlated with the serum levels of VEGF, MMP-11, and PDGF-C. Moreover, breast cancer dataset downloaded from The Cancer Genome Atlas showed that patients with higher level of MMP-11 or PDGF-C expression had shorter survival time than those with lower level of these proteins. In conclusion, IL-33 and sST2 may serve as noninvasive diagnosis markers for breast cancer. IL-33 and sST2 were significantly associated with MMP-11 or PDGF-C which indicated poor prognosis of breast cancer patients.
    Full-text · Article · Oct 2015 · Disease markers
  • Source
    • "The main cause of death in these patients was its metastases at distant sites. Owing to difficulty in predicting metathesis development many women are over-treated and suffer toxic side effects of chemotherapy (Weigelt et al., 2005). Recent epidemiological studies suggested the presence of an inverse association between regular intake of NSAIDs and the relative risk of breast cancer (Harris et al., 2005; Harris et al., 1995; Harris et al., 1996). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The study was devised to investigate the effect of retinoic acid trifloromethyl chalcone (RAFC) on mammary carcinogenesis in female rats. The data revealed a significant decrease in number of rats with mammary tumor, number of tumors per rat and tumor volume by 54, 72 and 75% respectively in RAFC group compared to control group. The ibuprofen treated rats also showed a significant decrease in number of rats with tumor, number of tumors per rat and tumor volumes by 43%, 55%, and 59%, respectively. Treatment of rats with RAFC also increased the latency period of tumor induction significantly. Median detection period (50% of tumors) was 92, 83 and 56 days respectively in the rats from RAFC, ibuprofen and control groups respectively after DMBA induction. These results demonstrate that RAFC possesses strong chemopreventive activity against mammary carcinogenesis. © 2015, Bangladesh Pharmacological Society. All right reserved.
    Preview · Article · Mar 2015 · Bangladesh Journal of Pharmacology
  • Source
    • "The main cause of mortality does not lie in the primary tumor, but rather metastasis to distant sites. Once the primary tumor is identified, about 15% of breast cancer patients develop distant metastatic disease in 3 years, and remain at risk for metastasis decades later (Weigelt et al. 2005). Despite metastasis being responsible for almost 90% of cancer-related deaths, there are many aspects of metastasis that remain undefined. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Most cancer deaths are a result of metastasis rather than the primary tumor. Although cigarette smoking has been determined as a risk factor for several cancers, its role in metastasis has not been studied in detail. We propose that cigarette smoking contributes to metastatic disease via inhibition of breast cancer cell platelet-activating factor acetylhydrolase (PAF-AH), resulting in PAF accumulation and a subsequent increase in cell motility. We studied several breast cell lines, including immortalized mammary epithelial cells (MCF-10A), luminal A hormone positive MCF-7, basal-like triple negative MDA-MB-468, and claudin-low triple-negative highly metastatic MDA-MB-231 breast tumor cells. We exposed cells to cigarette smoke extract (CSE) for up to 48 h. CSE inhibited PAF-AH activity, increased PAF accumulation, and increased cell motility in MDA-MB-231 metastatic triple negative breast cancer cells. The calcium-independent phospholipase A2 (iPLA2) inhibitor, (S) bromoenol lactone ((S)-BEL) was used to prevent the accumulation of PAF and further prevented the increase in cell motility seen previously when cells were exposed to CSE. Thus, iPLA2 or PAF may represent a therapeutic target to manage metastatic disease, particularly in triple-negative breast cancer patients who smoke. © 2015 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of the American Physiological Society and The Physiological Society.
    Full-text · Article · Mar 2015
Show more